Adaptive Biotechnologies Stock Forum

$Adaptive Biotechnologies (ADPT.US)$ OBLG guys!!!!

$Adaptive Biotechnologies (ADPT.US)$
Major Medicare Win: Adaptive's Cancer Test Gets 5-Year Coverage Extension

$Adaptive Biotechnologies (ADPT.US)$ Reuters
just
Adaptive Biotechnologies Receives Expanded Medicare Coverage of Clonoseq® for Surveillance in Mantle Cell Lymphoma

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Positive
Phase 3 trial data shows clonoSEQ can help avoid unnecessary transplantation procedures in MCL patients
FELIX study demonstrated 84% treatment response rate with MRD <10⁻⁶
Evidence supports clonoSEQ's effectiveness in early detection of disease progression
Data validates test'...

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Adaptive Biotechnologies (ADPT) presented new data at the 66th ASH Annual Meeting showcasing the effectiveness of their clonoSEQ® test in measuring residual disease (MRD) for blood cancer treatment. Key findings from multiple studies demonstrate that achieving MRD lev...

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...

$Adaptive Biotechnologies (ADPT.US)$ Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually...